Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Transgene

< Previous 1 2 Next >
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
From Transgene
Via Business Wire
Transgene Reports Business Update and Q3 2023 Financial Position
From Transgene
Via Business Wire
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
From Transgene
Via Business Wire
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
From Transgene
Via Business Wire
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
From Transgene
Via Business Wire
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
From Transgene
Via Business Wire
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Transgene
Via Business Wire
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
From Transgene
Via Business Wire
Transgene provides business update and Q1 2023 financial position
From Transgene
Via Business Wire
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
From Transgene
Via Business Wire
Transgene’s Combined General Meeting of May 5, 2023
From Transgene
Via Business Wire
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
From Transgene
Via Business Wire
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
From Transgene
Via Business Wire
Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
From Transgene
Via Business Wire
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
From Transgene
Via Business Wire
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
From Transgene
Via Business Wire
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene: 2022 Full-year Results and Business Update
From Transgene
Via Business Wire
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
From Transgene
Via Business Wire
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
From Transgene
Via Business Wire
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
From Transgene
Via Business Wire
Transgene Announces Financial Calendar for 2023
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
From Transgene
Via Business Wire
Transgene Reports Business Update And Q3 2022 Financial Position
From Transgene
Via Business Wire
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
From Transgene
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.